Key facts
- Logomix’s last known valuation is $46.1M (Mar 2025).
- It has raised $23.2M; the latest was Later Stage VC ($19.4M) in Mar 2025.
- Notable investors include Plug and Play Tech Center, Mitsubishi UFJ Capital, J-Startup, Berkeley SkyDeck, Sand Hill Angels — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Logomix
- ·The full record, as it builds
Funding rounds
No funding rounds for Logomix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Logomix
Operator of a synthetic biology company intended to reshape the landscape of human genome engineering and drive groundbreaking advancements. The company helps to introduce precise and extensive genetic alterations, targeting specific loci spanning megabases, and the transformative tool unlocks unparalleled possibilities in the development of revolutionary multi-functionalized cells for the fields of cell therapy and regenerative medicine, enabling medical researchers to have human cell engineering collaborations and partnerships to develop and optimize cell therapy modalities.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2019
- Employees
- 11
- Website
- logomix.bio/
- Ownership
- Privately Held (backing)
Logomix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Logomix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Logomix in its N-PORT filings yet. We sweep new filings monthly.